Cas:16083-79-7 [4,4,5,5,6,7,7,7-octafluoro-2-hydroxy-6-(trifluoromethyl)heptyl] 2-methylprop-2-enoate manufacturer & supplier

Chemical Name:[4,4,5,5,6,7,7,7-octafluoro-2-hydroxy-6-(trifluoromethyl)heptyl] 2-methylprop-2-enoate

CAS.NO:16083-79-7

Synonyms:MFCD00236097;pc6104d

Molecular Formula:C₁₂H₁₁F₁₁O₃

Molecular Weight:412.19600

HS Code:2916140000

Physical and Chemical Properties:

Melting point:N/A

Boiling point:271.8ºC at 760mmHg

Density:1.456g/cm3

Index of Refraction:n20/D 1.374(lit.)

PSA:46.53000

Exact Mass:412.05300

LogP:3.96020

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD00236097 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,pc6104d physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00236097 Use and application,pc6104d technical grade,usp/ep/jp grade.

Related News: With the continuous advancement of economic globalization, the division of labor and cooperation around the world has become increasingly apparent. The fine chemical industry has the foundation of global division of labor and cooperation due to its long and complex industrial chain. [4,4,5,5,6,7,7,7-octafluoro-2-hydroxy-6-(trifluoromethyl)heptyl] 2-methylprop-2-enoate manufacturer The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. [4,4,5,5,6,7,7,7-octafluoro-2-hydroxy-6-(trifluoromethyl)heptyl] 2-methylprop-2-enoate supplier In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of ��predictable�� clinical value for life-threatening diseases for which effective treatment is not immediately available. [4,4,5,5,6,7,7,7-octafluoro-2-hydroxy-6-(trifluoromethyl)heptyl] 2-methylprop-2-enoate vendor The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. [4,4,5,5,6,7,7,7-octafluoro-2-hydroxy-6-(trifluoromethyl)heptyl] 2-methylprop-2-enoate factory With the continuous advancement of economic globalization, the division of labor and cooperation around the world has become increasingly apparent. The fine chemical industry has the foundation of global division of labor and cooperation due to its long and complex industrial chain.